Cantex Pharmaceuticals, Inc. is dedicated and committed to its mission to develop proprietary compounds that enhance the efficacy and safety of the treatment of cancers and blood disorders, while reducing the life-threatening side effects of such treatments. As CEO, I am leading Cantex to capitalize on what I believe are multiple opportunities to address significant unmet medical needs in the treatment of malignant diseases.
Whether targeting cancer stem cells which are the source of cancer recurrence or resistance to available treatments, or targeting processes which produce or prolong unwanted and often dangerous side effects of cancer treatment, the experience, knowledge and creativity of Cantex’s management team permits us to identify and begin to develop cancer compounds with great therapeutic potential.
Despite advances in cancer treatment, the unmet medical need remains high. In cancer, cells divide in an uncontrolled fashion and can spread into surrounding tissues and distant areas of the body. Cancer stem cells, present in almost all major solid tumors and malignant blood disorders, have emerged as one of the most important targets for cancer treatment.
CX-02, our proprietary combination of disulfiram + copper, is highly toxic to a broad range of cancer stem cells, including those of glioblastoma, a highly malignant brain tumor and triple-negative breast cancer. Based upon the results of completed Phase I clinical trials, extensive pre-clinical data, and ready passage across the blood brain barrier, Cantex expects to initiate a Phase II trial of CX-02 in recurrent glioblastoma. Other clinical trials in metastatic triple-negative breast cancer including patients with brain metastases, and in other cancers are planned in 2017.
Clinical and pre-clinical studies have indicated the potential of Cantex’s other clinical stage product, CX-01, to accelerate platelet and white blood cell recovery when CX-01 is administered to patients receiving chemotherapy, and to increase the therapeutic effect of cancer chemotherapy. To date, the Company has completed an open-label, non-randomized Phase IIa clinical trial in acute myeloid leukemia (AML) where CX-01 was administered in combination with chemotherapy.
Cantex’s Executive Chairman, Neil Flanzraich, and I have strong records of developing successful products and companies. We strongly believe that Cantex has the necessary expertise, talent, and determination to develop medicines which significantly benefit cancer patients.
Stephen G. Marcus, M.D.
Chief Executive Officer
Cantex Pharmaceuticals, Inc.